July 24, 2017

Robby Booth of Glytec Discusses the Importance of Data-Sharing Capabilities

Data-sharing capabilities are important for faster communications and results that can greatly benefit the patient, says Robby Booth, senior vice president of research and development at Glytec.

Over the past few months, there have been some announcements that we’ve made. We have a partnership now with AgaMatrix, which is a Bluetooth glucose meter, to be able to capture their data from the cloud. We have a partnership with Livongo, which is a cellular meter, so we can capture that data from their cloud; and we have a partnership with Telcare, which is also a cellular meter.

June 8, 2017

AgaMatrix and Glytec Announce Partnership to Deliver a Cloud-Based Diabetes Management Platform to Improve Clinical Insights and Patient Blood Glucose Control

AgaMatrix, Inc. and Glytec announced today they are partnering to optimize clinical access to accurate glucose data and insulin titration support through a cloud-based diabetes management platform.

AgaMatrix is integrating their FDA-cleared Jazz Wireless 2 Bluetooth® Blood Glucose Monitoring System with Glytec’s eGlycemic Management System® (eGMS®), featuring FDA-cleared Glucommander™ for evidence-based insulin dosing decision support. By automatically transferring patient blood glucose data from the AgaMatrix Diabetes Manager App to eGMS®, health care professionals are able to deliver personalized diabetes therapy management in a virtual setting. The two companies are actively engaged in a pilot of this integrated solution.

April 18, 2017

Livongo Partnership With Glytec Supports Members and Their Providers With Insulin Titration

Livongo goes deeper into medication optimization.

Livongo Health, the leading consumer digital health company focused on empowering people with chronic conditions to live better and healthier lives, today announced a partnership with Glytec to offer eGlycemic Management System®, or eGMS®, to Livongo members. With this alliance, Livongo and Glytec will partner to deliver an expanded diabetes management solution that includes insulin titration, making managing diabetes easier for members and their providers.

February 16, 2017

New Research Further Validates Benefits of Personalized Diabetes Therapy Management Across the Continuum of Care

Two studies presented at the International Conference on Advanced Technologies & Treatments for Diabetes offer additional evidence of how Glytec’s disruptive technologies achieve dramatic and sustained impact on glucose control.

The 10th Annual International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2017) showcases additional evidence that use of Glytec’s patented eGlycemic Management System®, or eGMS®, leads to dramatic improvements in diabetes control and patient outcomes in both acute and outpatient settings. Two studies presented by diabetologist and researcher, Dr. Bruce Bode, find that personalized therapy management facilitated through Glytec’s eGMS® effectively reduces hemoglobin A1C, incidence of hypoglycemia and time to prescribed glucose target, all primary measures of diabetes control and patient outcomes.

October 4, 2016

Study Published by Journal of Diabetes Science and Technology Demonstrates Glytec’s Superiority in Meeting ADA Guidelines

Better patient outcomes point to use of a fully automated insulin dosing decision support system as the new standard of care for basal-bolus therapy.

A study published in the Journal of Diabetes Science and Technology (JDST) provides further evidence that Glytec’s patented eGlycemic Management System® (eGMS®) is safer and more effective than traditional approaches to managing basal-bolus therapy. With some 40% of hospitalized patients receiving insulin therapy during their stay, the consequences of inadequate and imprecise dosing — including increased risk of complications and mortality, longer lengths of stay, and higher readmission rates — pose significant cost and quality improvement opportunities for hospitals.

June 20, 2016

Glytec Presents Evidence on How Using Data to Deliver Insulin Improves Outcomes

Using an algorithm to recommend insulin dosing, both in and out of the hospital, was shown to improve glycemic control and aid population health management.

The march toward value-based care is occurring on many fronts, with diabetes quality metrics front and center. Providers from giant hospital systems to primary care practices are looking for ways to find savings—and make patients healthier. In this mix is Glytec, a 10-year-old company founded on the idea that taking guesswork and time out of insulin dosing, first in hospital settings and then outside them, could dramatically reduce episodes of hypo- and hyperglycemia. This would provide savings and lead to better glycated hemoglobin (A1C) levels for patients with previously uncontrolled diabetes.

June 16, 2016

Glytec’s Glucommander and eGlycemic Management System Featured in Five Studies Presented at The American Diabetes Association’s 76th Scientific Sessions

Wide range of studies further demonstrates significant impact in the emergency department, hospital and outpatient settings.

Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions, today announced that the company has presented five abstracts addressing a range of issues related to diabetes care at the American Diabetes Association’s 76th Scientific Sessions in New Orleans, Louisiana, June 10-14, 2016. The American Diabetes Association (ADA) brings together global leaders to discuss advancements in diabetes research and care.

November 9, 2015

Glucose Management by Software Proves Effective

A software system called Glucommander from Glytec Systems works well at titrating the right dose to bring blood sugar levels under control.

The company has now released results of a 30-day study for outpatients using the system in their homes. The subjects were given a glucometer that transmits data readings using a cellular data connection. The Glucommander system would then send the recommended dosage to the patient as a text message. The results of the test showed that 90% of the subjects in the study were able to achieve their target levels within three weeks.

November 3, 2015

Study of Glytec’s Glucommander in an Outpatient Setting Indicates Dramatic A1C Reductions

Ninety percent of study participants achieved target glucose within 3 weeks and achieved an average reduction in estimated A1C of 3.0%.

Glytec, the pioneer and leader in providing innovative glucose management software solutions, announced today that Glucommander™, a component of the company’s eGMS® platform, achieved its 30-day primary efficacy endpoint in a study evaluating the average A1C reduction in an outpatient setting for persons with type 1 and type 2 diabetes. According to study results, Glucommander was effective at titrating insulin doses and quickly achieving glucose control, with low rates of hypoglycemia, for 22 patients, regardless of the severity of their diabetes. The average starting A1C was 10.4% and the average estimated A1C (eA1C) at 30-days was 7.4%.

October 14, 2015

Glytec Receives Patent on Innovative Diabetes Management Mobile App

The allowed claims are directed to a system for glycemic control of a diabetic patient that includes a smartphone-based diabetes mobile application, which will provide patients with real-time insulin dosing guidance, leveraging Glytec’s proprietary insulin titration technology.

Glytec, the pioneer and leader in providing innovative glucose management software solutions, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering key aspects of the company’s core technology for diabetes management.

May 1, 2015

Renowned Diabetologist and Former Chairman of ADA Primary Care Advisory Group Joins Glytec Executive Team

Dr. Andrew S. Rhinehart to serve as Chief Medical Officer of Glytec.

Glytec, a clinical information technology company dedicated to improving insulin management and glycemic control for patients in hospitals and other care settings, today announced that Andrew S. Rhinehart, MD, FACP, CDE, BC-ADM, CDTC, has joined the company as the chief medical officer (CMO). In this role, Dr. Rhinehart will leverage his 20 years of clinical expertise to aid the development and innovation of Glytec’s suite of computerized, predictive dosing algorithms for IV, subcutaneous, and pediatric insulin dosing.